PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'OyaGen, Inc., Rochester, New York, USA.\', \'Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA.\', \'Center for Musculoskeletal Research, University of Rochester School of Medicine & Dentistry, Rochester, New York, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1172/jci.insight.153165e153165
?:hasPublicationType
?:journal
  • JCI insight
is ?:pmid of
?:pmid
?:pmid
  • 34807849
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34807849>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34807849>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all